E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute Antibody Mediated Rejection (AMR) in kidney transplant patients |
|
E.1.1.1 | Medical condition in easily understood language |
Graft rejection in kidney transplant patients |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10044439 |
E.1.2 | Term | Transplant rejection |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- Assessment of the safety and tolerability of Cinryze in kidney transplant patients with acute antibody-mediated rejection (AMR).
- Assessment of the efficacy of Cinryze for the treatment of acute AMR in kidney transplant patients.
- Examination of the pharmacokinetics and pharmacodynamics of Cinryze in kidney transplant patients with acute AMR. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- age : 18 years or older
- weight : above or equal to 50 kg
- Identified Human Leukocyte Antigen (HLA) donor-specific antibody (DSA)
- Achievement of adequate function of kidney transplant, as determined by creatinine clearance above or equal to 40 ml/min, within the first 4 weeks post-transplant
- First qualifying AMR episode, within 12 months after transplant
- Able to receive first dose of study drug, within 72 hours after the qualifying renal allograft biopsy that was diagnostic for AMR |
|
E.4 | Principal exclusion criteria |
- have received a deceased donor kidney with any of the following characteristics (Banff classification >=2 for arteriosclerosis, interstitial fibrosis or tubular atrophy ; pediatric and bloc kidney transplant)
- Rapid onset of severe oliguric AMR
- Any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results
- Any infection that causes hemodynamic compromise
- History of abnormal bleeding, clotting or any coagulopathy
- History of allergic reaction to C1 esterase inhibitor or other blood products
- Participation in the active dosing phase of any other investigational drug study within 30 days prior to dosing with the study drug
- Pregnancy or breastfeeding
- Within 48 hours prior to dosing with study drug, white blood cell count < 0.5*10e9/l or > 20*10e9/l
- Within 48 hours prior to dosing with study drug, platelet count < 25*10e9/l or > 600*10e9/l
- Receipt of any of the following AMR agents, within one month prior to the first dose of study drug : Eculizumab, Ecallantide, Bortezomib, any C1 esterase inhibitor
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Histopathology
- Graft function (creatinine clearance, serum creatinine)
- Rescue therapy (salvage spenectomy, plasmapheresis frequency)
- Clinical (allograft failure, overall survival) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- At Day 20, histopathology.
- At the end of the study, incidence of salvage splenectomy and clinical end-points (allograft failure, overall survival).
- Graft function at Days 3,5,7,9,11, 20 and 90 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |